Filing Flows › Xilio Therapeutics (XLO) › Q4 2025
Xilio Therapeutics (XLO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 23, 2026
Xilio Therapeutics (XLO) reported revenue of $13.7M for the fourth quarter 2025 (Q4 2025), +694% from a year earlier and -28% from the quarter before. Operating margin was -86.5%, net earnings $10.4M (75.7% of revenue).
Xilio Therapeutics, Q4 2025: revenue $13.7M (+694% year over year), operating margin -86.5%, net earnings $10.4M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.7M | -28% | +694% |
| Operating profit | −$11.8M | — | — |
| Net earnings | $10.4M | — | — |
| Operating cash flow | −$2.0M | — | — |
What changed
Revenue was $13.7M in Q4 2025, up 694% year over year and down 28% from the previous quarter.
Operating costs exceeded revenue by $11.8M, an operating margin of -86.5%. Total costs grew 66% against revenue growth of 694%. The fastest-growing cost line was Research & development (+105%). Net earnings were $10.4M. The effective tax rate was 0.0%. Non-operating items added $22.2M, 214% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$2.0M. Non-cash charges added back $323K of depreciation and amortization and $2.9M of share-based compensation. Working capital and other items used $15.6M. Capital expenditures of $95K exceeded it, leaving free cash flow of −$2.1M.
Questions
What was Xilio Therapeutics' revenue in the fourth quarter 2025?
Xilio Therapeutics (XLO) reported revenue of $13.7M for the fourth quarter 2025 (Q4 2025), +694% from a year earlier and -28% from the quarter before.
Was Xilio Therapeutics profitable in the fourth quarter 2025?
Operating loss was $11.8M (-86.5% of revenue) and net earnings $10.4M.
Source: Xilio Therapeutics 10-K on SEC EDGAR.